Evolutionary algorithms and artificial intelligence in drug discovery: opportunities, tools, and prospects Online publication date: Sun, 14-May-2023
by Moolchand Sharma; Suman Deswal
International Journal of Networking and Virtual Organisations (IJNVO), Vol. 27, No. 4, 2022
Abstract: The drug design process is lengthy, complex, and dependent on several factors. Developing a medicine can take 10 to 15 years, from discovery to commercialisation. Machine learning (ML) refers to a set of tools that can assist you in learning more and making better decisions for well-defined questions with a large amount of data. The opportunities to use ML occur throughout the drug development process. Examples include target identification and validation, identification of alternative targets, and biomarker identification. Some approaches have produced accurate predictions and insights, while others have not. But to deal with high-dimensional data, we need soft-computing methods to find the best solution, which could be a new drug. This article provides a detailed overview of various ML, evolutionary algorithms, and soft computing techniques surveyed and analysed for de novo drug design, emphasising the computational aspects.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Networking and Virtual Organisations (IJNVO):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook